BD (Becton, Dickinson and Company), a leading global medical technology company, is excited to showcase at CPhI Barcelona 2023 – building on its decades of expertise in partnering with the biopharmaceutical industry to advance drug delivery excellence.
CPhI will be held in Barcelona, Spain from October 24 to October 26, 2023. The conference will focus on the latest pharmaceutical packaging innovations and drug delivery devices. At the booth, BD will share our wide portfolio of products, services and integrated solutions to help meet the needs of pharma and biotech companies developing combination products. BD experts will be on site to discuss a variety of topics related to the next generation of drug delivery.
· For vaccination needs, we have a wide portfolio of prefillable syringes (PFS) including BD Effivax™ Glass Prefillable Syringe – a next-generation glass prefillable syringe that has been designed in collaboration with leading pharmaceutical companies to meet the complex and evolving needs of vaccine manufacturing. BD Effivax™ Glass Prefillable Syringe sets a new standard in performance for vaccine PFS with new and tightened specifications for processability, cosmetics, and integrity.(1)
· BD is working to support the delivery of medications that address chronic disease outcomes in areas such as diabetes, obesity, oncology and autoimmune disorders, and also to meet the need for technologies that enable care to be delivered in new settings. Our advanced drug delivery systems portfolio offers self-injection systems that support the subcutaneous delivery of drugs across a broad range of volume and viscosity needs, including BD Libertas™ Wearable injector* – designed for the subcutaneous delivery of large volume, high viscosity biologics in a single-use, disposable “ready to use” system for patient administration with no assembly required (2) and BD Evolve™ On-body Injector* – a programmable, variable dose on-body injector. It offers pharmaceutical companies a wearable solution that enables new delivery formats in alternate settings and is designed to enable subcutaneous administration of up to 3 mL of medication, with up to three days of wear. (3)
· We also help our customers who want to co-pack or co-deliver administration devices with their drugs. Typically, they do so to support proper administration, or as a service to the end user, or to control the drug administration material - e.g., in clinical trials. We provide reconstitution, injection and infusion devices. Our devices may for example be used for complex administration routes (such as ophthalmic drug reconstitution), as well as for cell and gene therapies (C>), home use of chronic drugs, and vaccination campaigns.
· A complete range of services will be showcased across BD Pharmaceutical Services and Solutions and ZebraSci™Read More
[2', 3'-diTBDMS-C(Ac)]](https://eimg.pharmasources.com/image/product/20231227/5569723496509e0380118a109ff72ce1jpg)
(All Rights Reserved)